Therapeutic effect on idiopathic sudden sensorineural hearing loss with duration of onset more than 3 months.

The purpose of this study was to evaluate the therapeutic efficacy and stability upon idiopathic sudden sensorineural hearing loss (ISSNHL) patients with duration of onset more than 3 months. Twenty-eight patients diagnosed as ISSNHL were treated by intravenous injection and another 26 by oral medication. Pure tone tests were undertaken at pre-therapy, the 3rd, 7th, 10th, 14th day of post-treatment, and 1 and 2 months of follow-up respectively. A total of 54 ISSNHL patients with duration of onset ranged from 3 months to 19 years were concerned. In the group administrated by intravenous injection, the total effective rate was 64.29 % including 2 cases total recovery, 3 excellent and 13 partial recovery. In the oral administration group, there was no recovery or excellence case, and 8 (30.77 %) showed partial recovery. There was significant difference between the two groups in total effective rates (P < 0.05). The treatment efficacy were stable in both two groups, and the difference in stability was no statistical significance (P = 0.397). There was therapeutic value for ISSNHL duration of onset more than 3 months, especially for patients with mild and moderate hearing loss. The administration by intravenous injection should be the optimization.